ଉଇକିପିଡ଼ିଆ

ଟିର୍ଜେପାଟାଇଡ

(Tirzepatideରୁ ଲେଉଟି ଆସିଛି)

ଟିର୍ଜେପାଟାଇଡ, ଏକ ବିକ୍ରିୟ ନାମ ମୁଞ୍ଜାରୋ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଟାଇପ୍-୨ ମଧୁମେହର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । [୧] ଏହା ଉପ‌ଯୁକ୍ତ ଖାଦ୍ୟ ଏବଂ ବ୍ୟାୟାମ ସହିତ ଏକତ୍ର ବ୍ୟବହୃତ ହୁଏ । [୧] ଚର୍ମ ତଳ ଇଞ୍ଜେକ୍ସନ ଆକାରରେ ସପ୍ତାହକୁ ଥରେ ଦିଆଯାଏ ।[୧]

ଟିର୍ଜେପାଟାଇଡ
Clinical data
Trade namesMounjaro
SynonymsLY3298176, GIP/GLP-1 RA
data
Routes of
administration		Subcutaneous
Legal status
Legal status
Pharmacokinetic data
Bioavailability80%
Protein bindingAlbumin
MetabolismProteolytic cleavage, β-oxidation of fatty diacid section and amide hydrolysis
Elimination half-lifeFive days
ExcretionUrine and faeces
Identifiers
  • (2S)-2-[[20-[[(5S)-6-[[(2S,3S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-2-methylpropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-6-oxohexyl]amino]-20-oxoicosanoyl]amino]-5-[2-[2-[2-[2-[2-(carboxymethoxy)ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-5-oxopentanoic acid
Chemical and physical data
FormulaC225H348N48O68
Molar mass୪,୮୧୩.୫୩ g·mol−1
3D model (JSmol)
  • C[C@@H](O)[C@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1C=CC(O)=CC=1)C(=O)N[C@@H](CC1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NC(C)(C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCCCC(O)=O)C(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2C=CC=CC1=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O
  • InChI=1S/C225H348N48O68/c1-23-126(10)183(264-198(311)146(64-50-52-88-226)246-202(315)157(109-180(297)298)252-199(312)152(103-124(6)7)261-223(337)225(21,22)269-217(330)185(128(12)25-3)266-209(322)163(120-278)257-200(313)153(107-138-74-78-141(282)79-75-138)250-203(316)158(110-181(299)300)253-207(320)162(119-277)259-216(329)187(134(18)280)267-206(319)155(106-136-60-44-41-45-61-136)254-215(328)186(133(17)279)262-174(289)114-237-193(306)147(83-87-179(295)296)260-222(336)224(19,20)268-192(305)143(227)104-137-72-76-140(281)77-73-137)214(327)242-131(15)190(303)244-148(80-84-168(228)283)196(309)245-145(65-51-53-89-231-175(290)121-340-100-99-339-97-91-233-176(291)122-341-101-98-338-96-90-232-170(285)86-82-150(221(334)335)243-171(286)70-46-38-36-34-32-30-28-26-27-29-31-33-35-37-39-47-71-178(293)294)195(308)240-130(14)191(304)248-154(105-135-58-42-40-43-59-135)205(318)263-182(125(8)9)212(325)247-149(81-85-169(229)284)197(310)251-156(108-139-111-234-144-63-49-48-62-142(139)144)201(314)249-151(102-123(4)5)204(317)265-184(127(11)24-2)213(326)241-129(13)189(302)236-112-172(287)235-115-177(292)270-92-54-66-164(270)210(323)258-161(118-276)208(321)256-160(117-275)194(307)238-113-173(288)239-132(16)218(331)272-94-56-68-166(272)220(333)273-95-57-69-167(273)219(332)271-93-55-67-165(271)211(324)255-159(116-274)188(230)301/h40-45,48-49,58-63,72-79,111,123-134,143,145-167,182-187,234,274-282H,23-39,46-47,50-57,64-71,80-110,112-122,226-227H2,1-22H3,(H2,228,283)(H2,229,284)(H2,230,301)(H,231,290)(H,232,285)(H,233,291)(H,235,287)(H,236,302)(H,237,306)(H,238,307)(H,239,288)(H,240,308)(H,241,326)(H,242,327)(H,243,286)(H,244,303)(H,245,309)(H,246,315)(H,247,325)(H,248,304)(H,249,314)(H,250,316)(H,251,310)(H,252,312)(H,253,320)(H,254,328)(H,255,324)(H,256,321)(H,257,313)(H,258,323)(H,259,329)(H,260,336)(H,261,337)(H,262,289)(H,263,318)(H,264,311)(H,265,317)(H,266,322)(H,267,319)(H,268,305)(H,269,330)(H,293,294)(H,295,296)(H,297,298)(H,299,300)(H,334,335)/t126-,127-,128-,129-,130-,131-,132-,133+,134+,143-,145-,146-,147-,148-,149-,150+,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,182-,183-,184-,185-,186-,187-/m0/s1
  • Key:BTSOGEDATSQOAF-SMAAHMJQSA-N

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ବାନ୍ତି, ତରଳ ଝାଡ଼ା, କୋଷ୍ଠକାଠିନ୍ୟ ଏବଂ ପେଟ ଯନ୍ତ୍ରଣା ହୋଇପାରେ ।[୧] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅଗ୍ନାଶୟ ପ୍ରଦାହ, କମ୍ ରକ୍ତ ଶର୍କରା, ଆଲର୍ଜି ପ୍ରତିକ୍ରିୟା ଏବଂ ପିତ୍ତ କୋଷ ରୋଗ ହୋଇପାରେ । [୧] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ । [୧] ଏହା ଏକ ଗ୍ଲୁକାଗନ୍ ସମ ପେପ୍ଟାଇଡ୍ -୧ (GLP-1) ଏବଂ ଗ୍ଲୁକୋଜ୍-ନିର୍ଭରଶୀଳ ଇନସୁଲିନୋଟ୍ରୋପିକ୍ ପଲିପେପ୍ଟାଇଡ୍ (GIP) ରିସେପ୍ଟର ଆକ୍ଟିଭେଟର ଯାହା ଖାଦ୍ୟ ଖାଇଲେ ଇନସୁଲିନ୍ ରିଲିଜ ହୋଇଥାଏ ।[୧] [୩]

୨୦୨୨ ମସିହାରେ ଏହା ଆମେରିକା, ୟୁରୋପ ଏବଂ ବ୍ରିଟେନରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଅନୁମୋଦିତ ହୋଇଥିଲା ।[୧][୩] [୪] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହାର ୪ ସପ୍ତାହ ଚିକିତ୍ସା ଖର୍ଚ୍ଚ ପ୍ରାୟ ୧,୦୦୦ ଆମେରିକୀୟ ଡଲାର ।[୫]

ଆଧାର

ସମ୍ପାଦନା
  1. ↑ ୧.୦ ୧.୧ ୧.୨ ୧.୩ ୧.୪ ୧.୫ ୧.୬ ୧.୭ ୧.୮ "Mounjaro- tirzepatide injection, solution". DailyMed. 13 May 2022. Archived from the original on 3 July 2022. Retrieved 27 May 2022.
  2. ↑ "FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes". U.S. Food and Drug Administration (FDA) (Press release). 13 May 2022. Archived from the original on 13 May 2022. Retrieved 13 May 2022.   This article incorporates text from this source, which is in the public domain.
  3. ↑ ୩.୦ ୩.୧ "Mounjaro". Archived from the original on 12 December 2022. Retrieved 12 December 2022.
  4. ↑ "Tirzepatide". SPS - Specialist Pharmacy Service. 8 March 2019. Archived from the original on 12 December 2022. Retrieved 12 December 2022.
  5. ↑ "Mounjaro Prices, Coupons, Copay & Patient Assistance". Drugs.com (in ଇଂରାଜୀ). Retrieved 12 December 2022.
"https://or.wikipedia.org/w/index.php?title=ଟିର୍ଜେପାଟାଇଡ&oldid=528775"ରୁ ଅଣାଯାଇଅଛି